SPRY1 and SPRY2 were shown to be downregulated in a variety of cancers, including liver, prostate, and lung tumors, implying a unique tumor-suppressive function (Montico et al., 2020).﻿ Conversely, SPRY1′s high expression in tumors harboring Ras/Raf mutations to tumor progression (He et al., 2016) suggests its role in cancer malignancy. Here, SPRY2 is linked to cancer.